Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52


Control of Candida auris in healthcare institutions: Outcome of an International Society for Antimicrobial Chemotherapy expert meeting.

Kenters N, Kiernan M, Chowdhary A, Denning DW, Pemán J, Saris K, Schelenz S, Tartari E, Widmer A, Meis JF, Voss A.

Int J Antimicrob Agents. 2019 Oct;54(4):400-406. doi: 10.1016/j.ijantimicag.2019.08.013. Epub 2019 Aug 13. Review.


In vitro antifungal activity of a novel topical triazole PC945 against emerging yeast Candida auris.

Rudramurthy SM, Colley T, Abdolrasouli A, Ashman J, Dhaliwal M, Kaur H, Armstrong-James D, Strong P, Rapeport G, Schelenz S, Ito K, Chakrabarti A.

J Antimicrob Chemother. 2019 Oct 1;74(10):2943-2949. doi: 10.1093/jac/dkz280.


ECMM CandiReg-A ready to use platform for outbreaks and epidemiological studies.

Koehler P, Arendrup MC, Arikan-Akdagli S, Bassetti M, Bretagne S, Klingspor L, Lagrou K, Meis JF, Rautemaa-Richardson R, Schelenz S, Hamprecht A, Koehler FC, Kurzai O, Salmanton-García J, Vehreschild JJ, Alanio A, Alastruey-Izquierdo A, Arsic Arsenijevic V, Gangneux JP, Gow NAR, Hadina S, Hamal P, Johnson E, Klimko N, Lass-Flörl C, Mares M, Özenci V, Papp T, Roilides E, Sabino R, Segal E, Talento AF, Tortorano AM, Verweij PE, Hoenigl M, Cornely OA; European Confederation of Medical Mycology (ECMM).

Mycoses. 2019 Oct;62(10):920-927. doi: 10.1111/myc.12963. Epub 2019 Aug 1.


National mycology laboratory diagnostic capacity for invasive fungal diseases in 2017: Evidence of sub-optimal practice.

Schelenz S, Owens K, Guy R, Rautemaa-Richardson R, Manuel RJ, Richardson M, Moore C, Enoch DA, Micallef C, Howard P, Agrawal SG, Johnson EM, Muller-Pebody B; English Surveillance Programme for Antimicrobial Utilisation and Resistance (ESPAUR).

J Infect. 2019 Aug;79(2):167-173. doi: 10.1016/j.jinf.2019.06.009. Epub 2019 Jun 21.


Rapid and extensive karyotype diversification in haploid clinical Candida auris isolates.

Bravo Ruiz G, Ross ZK, Holmes E, Schelenz S, Gow NAR, Lorenz A.

Curr Genet. 2019 Oct;65(5):1217-1228. doi: 10.1007/s00294-019-00976-w. Epub 2019 Apr 24.


Ficolins and the Recognition of Pathogenic Microorganisms: An Overview of the Innate Immune Response and Contribution of Single Nucleotide Polymorphisms.

Bidula S, Sexton DW, Schelenz S.

J Immunol Res. 2019 Feb 5;2019:3205072. doi: 10.1155/2019/3205072. eCollection 2019. Review.


Posaconazole for the treatment of allergic bronchopulmonary aspergillosis in patients with cystic fibrosis.

Periselneris J, Nwankwo L, Schelenz S, Shah A, Armstrong-James D.

J Antimicrob Chemother. 2019 Jun 1;74(6):1701-1703. doi: 10.1093/jac/dkz075.


High prevalence of triazole resistance in clinical Aspergillus fumigatus isolates in a specialist cardiothoracic centre.

Abdolrasouli A, Scourfield A, Rhodes J, Shah A, Elborn JS, Fisher MC, Schelenz S, Armstrong-James D.

Int J Antimicrob Agents. 2018 Nov;52(5):637-642. doi: 10.1016/j.ijantimicag.2018.08.004. Epub 2018 Aug 10.


A Prospective Real-World Study of the Impact of an Antifungal Stewardship Program in a Tertiary Respiratory-Medicine Setting.

Nwankwo L, Periselneris J, Cheong J, Thompson K, Darby P, Leaver N, Schelenz S, Armstrong-James D.

Antimicrob Agents Chemother. 2018 Sep 24;62(10). pii: e00402-18. doi: 10.1128/AAC.00402-18. Print 2018 Oct.


Author Correction: Genomic epidemiology of the UK outbreak of the emerging human fungal pathogen Candida auris.

Rhodes J, Abdolrasouli A, Farrer RA, Cuomo CA, Aanensen DM, Armstrong-James D, Fisher MC, Schelenz S.

Emerg Microbes Infect. 2018 May 31;7(1):104. doi: 10.1038/s41426-018-0098-x.


Airway persistence by the emerging multi-azole-resistant Rasamsonia argillacea complex in cystic fibrosis.

Abdolrasouli A, Bercusson AC, Rhodes JL, Hagen F, Buil JB, Tang AYY, de Boer LL, Shah A, Milburn AJ, Elborn JS, Jones AL, Meis JF, Fisher MC, Schelenz S, Simmonds NJ, Armstrong-James D.

Mycoses. 2018 Sep;61(9):665-673. doi: 10.1111/myc.12789. Epub 2018 Jun 20.


Genomic epidemiology of the UK outbreak of the emerging human fungal pathogen Candida auris.

Rhodes J, Abdolrasouli A, Farrer RA, Cuomo CA, Aanensen DM, Armstrong-James D, Fisher MC, Schelenz S.

Emerg Microbes Infect. 2018 Mar 29;7(1):43. doi: 10.1038/s41426-018-0045-x. Erratum in: Emerg Microbes Infect. 2018 May 31;7(1):104.


Candida auris: a Review of the Literature.

Jeffery-Smith A, Taori SK, Schelenz S, Jeffery K, Johnson EM, Borman A; Candida auris Incident Management Team, Manuel R, Brown CS.

Clin Microbiol Rev. 2017 Nov 15;31(1). pii: e00029-17. doi: 10.1128/CMR.00029-17. Print 2018 Jan. Review.


An investigation of antifungal stewardship programmes in England.

Micallef C, Ashiru-Oredope D, Hansraj S, Denning DW, Agrawal SG, Manuel RJ, Schelenz S, Guy R, Muller-Pebody B, Patel R, Howard P, Hopkins S, Johnson E, Enoch DA.

J Med Microbiol. 2017 Nov;66(11):1581-1589. doi: 10.1099/jmm.0.000612. Epub 2017 Oct 25.


In vitro efficacy of disinfectants utilised for skin decolonisation and environmental decontamination during a hospital outbreak with Candida auris.

Abdolrasouli A, Armstrong-James D, Ryan L, Schelenz S.

Mycoses. 2017 Nov;60(11):758-763. doi: 10.1111/myc.12699. Epub 2017 Sep 15.


Yeasticidal activity of chemical disinfectants and antiseptics against Candida auris.

Moore G, Schelenz S, Borman AM, Johnson EM, Brown CS.

J Hosp Infect. 2017 Dec;97(4):371-375. doi: 10.1016/j.jhin.2017.08.019. Epub 2017 Sep 1.


Insidious Risk of Severe Mycobacterium chimaera Infection in Cardiac Surgery Patients.

Chand M, Lamagni T, Kranzer K, Hedge J, Moore G, Parks S, Collins S, Del Ojo Elias C, Ahmed N, Brown T, Smith EG, Hoffman P, Kirwan P, Mason B, Smith-Palmer A, Veal P, Lalor MK, Bennett A, Walker J, Yeap A, Isidro Carrion Martin A, Dolan G, Bhatt S, Skingsley A, Charlett A, Pearce D, Russell K, Kendall S, Klein AA, Robins S, Schelenz S, Newsholme W, Thomas S, Collyns T, Davies E, McMenamin J, Doherty L, Peto TE, Crook D, Zambon M, Phin N.

Clin Infect Dis. 2017 Feb 1;64(3):335-342. doi: 10.1093/cid/ciw754. Epub 2016 Dec 7. Erratum in: Clin Infect Dis. 2017 Sep 1;65(5):875.


First hospital outbreak of the globally emerging Candida auris in a European hospital.

Schelenz S, Hagen F, Rhodes JL, Abdolrasouli A, Chowdhary A, Hall A, Ryan L, Shackleton J, Trimlett R, Meis JF, Armstrong-James D, Fisher MC.

Antimicrob Resist Infect Control. 2016 Oct 19;5:35. eCollection 2016.


A Sweet Response to a Sour Situation: The Role of Soluble Pattern Recognition Receptors in the Innate Immune Response to Invasive Aspergillus fumigatus Infections.

Bidula S, Schelenz S.

PLoS Pathog. 2016 Jul 14;12(7):e1005637. doi: 10.1371/journal.ppat.1005637. eCollection 2016 Jul. Review. No abstract available.


Pseudomonas aeruginosa infection in cystic fibrosis: pathophysiological mechanisms and therapeutic approaches.

Lund-Palau H, Turnbull AR, Bush A, Bardin E, Cameron L, Soren O, Wierre-Gore N, Alton EW, Bundy JG, Connett G, Faust SN, Filloux A, Freemont P, Jones A, Khoo V, Morales S, Murphy R, Pabary R, Simbo A, Schelenz S, Takats Z, Webb J, Williams HD, Davies JC.

Expert Rev Respir Med. 2016 Jun;10(6):685-97. doi: 10.1080/17476348.2016.1177460. Epub 2016 May 13. Review.


Serum opsonin ficolin-A enhances host-fungal interactions and modulates cytokine expression from human monocyte-derived macrophages and neutrophils following Aspergillus fumigatus challenge.

Bidula S, Sexton DW, Schelenz S.

Med Microbiol Immunol. 2016 Apr;205(2):133-42. doi: 10.1007/s00430-015-0435-9. Epub 2015 Sep 4.


H-ficolin binds Aspergillus fumigatus leading to activation of the lectin complement pathway and modulation of lung epithelial immune responses.

Bidula S, Sexton DW, Yates M, Abdolrasouli A, Shah A, Wallis R, Reed A, Armstrong-James D, Schelenz S.

Immunology. 2015 Oct;146(2):281-91. doi: 10.1111/imm.12501. Epub 2015 Aug 24.


British Society for Medical Mycology best practice recommendations for the diagnosis of serious fungal diseases.

Schelenz S, Barnes RA, Barton RC, Cleverley JR, Lucas SB, Kibbler CC, Denning DW; British Society for Medical Mycology.

Lancet Infect Dis. 2015 Apr;15(4):461-74. doi: 10.1016/S1473-3099(15)70006-X. Epub 2015 Mar 12. Review.


The serum opsonin L-ficolin is detected in lungs of human transplant recipients following fungal infections and modulates inflammation and killing of Aspergillus fumigatus.

Bidula S, Sexton DW, Abdolrasouli A, Shah A, Reed A, Armstrong-James D, Schelenz S.

J Infect Dis. 2015 Jul 15;212(2):234-46. doi: 10.1093/infdis/jiv027. Epub 2015 Jan 22.


Sustainable intensive thermal use of the shallow subsurface-a critical view on the status quo.

Vienken T, Schelenz S, Rink K, Dietrich P.

Ground Water. 2015 May-Jun;53(3):356-61. doi: 10.1111/gwat.12206. Epub 2014 May 14.


Unilateral cacosmia: a presentation of maxillary fungal infestation.

Erskine SE, Schelenz S, Philpott CM.

BMJ Case Rep. 2013 Apr 5;2013. pii: bcr2013008808. doi: 10.1136/bcr-2013-008808.


Role of ficolin-A and lectin complement pathway in the innate defense against pathogenic Aspergillus species.

Bidula S, Kenawy H, Ali YM, Sexton D, Schwaeble WJ, Schelenz S.

Infect Immun. 2013 May;81(5):1730-40. doi: 10.1128/IAI.00032-13. Epub 2013 Mar 11.


Longitudinal surveillance of bacteraemia in haematology and oncology patients at a UK cancer centre and the impact of ciprofloxacin use on antimicrobial resistance.

Schelenz S, Nwaka D, Hunter PR.

J Antimicrob Chemother. 2013 Jun;68(6):1431-8. doi: 10.1093/jac/dkt002. Epub 2013 Feb 8.


An antibiotic formulary for a tertiary care foot clinic: admission avoidance using intramuscular antibiotics for borderline foot infections in people with diabetes.

Gooday C, Hallam C, Sieber C, Mtariswa L, Turner J, Schelenz S, Murchison R, Messenger G, Morrow D, Hutchinson R, Williams H, Dhatariya K.

Diabet Med. 2013 May;30(5):581-9. doi: 10.1111/dme.12074. Epub 2013 Feb 28.


Opsonizing properties of rat ficolin-A in the defence against Cryptococcus neoformans.

Schelenz S, Kirchhof N, Bidula S, Wallis R, Sexton DW.

Immunobiology. 2013 Apr;218(4):477-83. doi: 10.1016/j.imbio.2012.06.006. Epub 2012 Jun 21.


Epidemiology, management and economic impact of febrile neutropenia in oncology patients receiving routine care at a regional UK cancer centre.

Schelenz S, Giles D, Abdallah S.

Ann Oncol. 2012 Jul;23(7):1889-93. doi: 10.1093/annonc/mdr520. Epub 2011 Nov 2.


In vitro antifungal activity of DNA topoisomerase inhibitors.

Steverding D, Evans P, Msika L, Riley B, Wallington J, Schelenz S.

Med Mycol. 2012 Apr;50(3):333-6. doi: 10.3109/13693786.2011.609186. Epub 2011 Sep 22.


Epidemiology of oral yeast colonization and infection in patients with hematological malignancies, head neck and solid tumors.

Schelenz S, Abdallah S, Gray G, Stubbings H, Gow I, Baker P, Hunter PR.

J Oral Pathol Med. 2011 Jan;40(1):83-9. doi: 10.1111/j.1600-0714.2010.00937.x. Epub 2010 Oct 4.


Oseltamivir-resistant pandemic (H1N1) 2009 in patient with impaired immune system.

Hill-Cawthorne GA, Schelenz S, Lawes M, Dervisevic S.

Emerg Infect Dis. 2010 Jul;16(7):1185-6. doi: 10.3201/eid1607.091579. No abstract available.


In vitro effect of DNA topoisomerase inhibitors on Candida albicans.

Kwok SC, Schelenz S, Wang X, Steverding D.

Med Mycol. 2010 Feb;48(1):155-60. doi: 10.3109/13693780903114934.


Standards of care for patients with invasive fungal infections within the United Kingdom: a national audit.

Schelenz S, Barnes RA, Kibbler CC, Jones BL, Denning DW.

J Infect. 2009 Feb;58(2):145-53. doi: 10.1016/j.jinf.2008.12.006. Epub 2009 Jan 29.


Management of candidiasis in the intensive care unit.

Schelenz S.

J Antimicrob Chemother. 2008 Jan;61 Suppl 1:i31-4. doi: 10.1093/jac/dkm430. Review.


Internet treatment of sexually transmitted infections - a public health hazard?

Vivancos R, Schelenz S, Loke YK.

BMC Public Health. 2007 Nov 15;7:333.


A systematic review of the clinical, public health and cost-effectiveness of rapid diagnostic tests for the detection and identification of bacterial intestinal pathogens in faeces and food.

Abubakar I, Irvine L, Aldus CF, Wyatt GM, Fordham R, Schelenz S, Shepstone L, Howe A, Peck M, Hunter PR.

Health Technol Assess. 2007 Sep;11(36):1-216. Review.


Septic arthritis due to extended spectrum beta lactamase producing Klebsiella pneumoniae.

Schelenz S, Bramham K, Goldsmith D.

Joint Bone Spine. 2007 May;74(3):275-8. Epub 2007 Mar 15. Review.


Streptococcus mutans endocarditis: beware of the 'diphtheroid'.

Schelenz S, Page AJ, Emmerson AM.

J R Soc Med. 2005 Sep;98(9):420-1. No abstract available.


Diagnosis and treatment of fungal endophthalmitis: a reassessment.

Schelenz S, Watson N.

Clin Infect Dis. 2005 Jul 15;41(2):274-5; author reply 275-6. No abstract available.


Significant reduction of endemic MRSA acquisition and infection in cardiothoracic patients by means of an enhanced targeted infection control programme.

Schelenz S, Tucker D, Georgeu C, Daly S, Hill M, Roxburgh J, French GL.

J Hosp Infect. 2005 Jun;60(2):104-10.


Portal vein thrombosis despite anticoagulation in a person with diabetes.

Schweigart JH, Klotsas A, Schelenz S, Dhatariya K.

J R Soc Med. 2005 Apr;98(4):161-3. Review. No abstract available.


Candidaemia in a London teaching hospital: analysis of 128 cases over a 7-year period.

Schelenz S, Gransden WR.

Mycoses. 2003;46(9-10):390-6.


Infective endocarditis in dialysis patients: new challenges and old.

Doulton T, Sabharwal N, Cairns HS, Schelenz S, Eykyn S, O'Donnell P, Chambers J, Austen C, Goldsmith DJ.

Kidney Int. 2003 Aug;64(2):720-7.


Hospital Infection Society International Activities. Argentina - British infection control experience.

Schelenz S.

J Hosp Infect. 2000 Apr;44(4):317-8. No abstract available.


Supplemental Content

Loading ...
Support Center